The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Immortal time bias in a claims-database study — one year on

This is a generated summary. It shows the 7 most-liked posts from a topic of 47, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
V
VPoulsenTL3Regular28 Jun 2026#1

Posting this under the heading it deserves: Immortal time bias in a claims-database study — one year on Everything below is what sits behind that.

Comparing SURPASS-2 (N Engl J Med, 2021) with SURMOUNT-1 (N Engl J Med, 2022) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

26 likes 30d
MD
methods_draftTL2Member30 Jun 2026#2

Confounding: in observational data, is there a third variable that explains the apparent association? In randomised data, randomisation should balance unknown confounders, though known confounders can be adjusted for.

28 likes 28d
PT
p.trevinoTL2 Moderator Solution2 Jul 2026#5

Criticise the method, not the author: a paper with a weak design is not a bad paper by someone with bad intentions. It is a paper that answers a limited question. Sometimes that is what the sponsor wanted, sometimes the researchers did the best they could with constraints.

20 likes 26d
YA
y.adeyemiTL2 Moderator5 Jul 2026#9

Generalisability: do the inclusion/exclusion criteria narrow the population so much that results do not apply to real people asking about it? This is a fair criticism but requires specificity about which real people and why the difference matters.

27 likes 22d
K
KTurkingtonTL3Regular8 Jul 2026#12

Defending a paper against criticism: if the authors respond, they might clarify something the paper explained poorly. Their response might also miss your point. Either way, the exchange in public is more useful than quiet disagreement.

26 likes 20d
JR
j.rasmussenTL2Regular15 Jul 2026#25

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

31 likes 12d
JP
j.petrovTL2 Moderator18 Jul 2026#30
m.marchetti, post #3: I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient. Go to post

I read post #28 twice before replying, because I had assumed the opposite.

Generalisability: do the inclusion/exclusion criteria narrow the population so much that results do not apply to real people asking about it? This is a fair criticism but requires specificity about which real people and why the difference matters.

24 likes in reply to #3 10d

Read the full topic (47 posts)

Moved from Trials by hana.sato. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

TopicParticipantsRepliesViewsActivity
Immortal time bias in a claims-database study
Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
MACDSOIDNN+29 34 28k 11mo
Measurement error in a self-reported exposure
Posting this under the heading it deserves: Measurement error in a self-reported exposure Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before…
LHCKSVCW+117 129 45k 5mo
Selection into a registry and what it does to the estimate
Selection into a registry and what it does to the estimate — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
SSLMAA 2 55k 7mo
Coming back to: A structured critique template this community uses
Posting this under the heading it deserves: A structured critique template this community uses Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with SURMOUNT-1 ( N Engl J Med , 2022)…
SOFAKHASMY+63 69 17k 18h
Critiquing an observational claim about a class effect — one year on
Critiquing an observational claim about a class effect — one year on — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…
FELDKRAWDO+5 9 3.2k 8mo

Related topics — sharing the tags effect size, risk of bias, confounding

TopicParticipantsRepliesViewsActivity
A plateau that disappeared when I changed how I measured — the long version
A plateau that disappeared when I changed how I measured — the long version — setting out what I have, and where I think it stops being reliable. Longitudinal report with the method stated, because a number…
YRFKLWVNNR+49 54 9.4k 1mo
Journal club: what we got wrong in an earlier session
On the subject in the title: Journal club: what we got wrong in an earlier session Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before posting; the…
NAFPALVSFT+114 125 2.5k 23h
A 40-week log with the measurement method stated — what changed since
A 40-week log with the measurement method stated — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Longitudinal report with the method stated, because a…
PTSMTSWMBP+9 13 2.1k 9h
Second pass at: Multiplicity when you track fifteen variables
Posting this under the heading it deserves: Second pass at: Multiplicity when you track fifteen variables Everything below is what sits behind that. I have seen SCALE ( N Engl J Med , 2015) cited in support…
KFFFRM 2 12k 18mo
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide
Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA ,…
UCZACNSKGF+72 77 7.2k 19mo